TScan Therapeutics’ (TCRX) Outperform Rating Reiterated at Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They currently have a $7.00 price objective on the stock. Wedbush’s price target points to a potential upside of 140.55% from the stock’s previous close.

Several other equities research analysts have also weighed in on TCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Stock Down 3.3 %

NASDAQ TCRX opened at $2.91 on Monday. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69. The company has a market capitalization of $155.31 million, a price-to-earnings ratio of -2.75 and a beta of 0.79. The stock’s 50 day moving average is $4.51 and its two-hundred day moving average is $5.60. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. Equities analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Great Point Partners LLC increased its position in TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock valued at $5,062,000 after acquiring an additional 75,544 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of TScan Therapeutics by 8.1% during the third quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock worth $4,849,000 after purchasing an additional 72,967 shares in the last quarter. Checkpoint Capital L.P. bought a new stake in shares of TScan Therapeutics during the third quarter valued at approximately $4,110,000. State Street Corp increased its holdings in shares of TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares in the last quarter. Finally, abrdn plc increased its holdings in shares of TScan Therapeutics by 27.2% in the third quarter. abrdn plc now owns 371,655 shares of the company’s stock valued at $1,851,000 after purchasing an additional 79,511 shares in the last quarter. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.